| Print
Vanda Pharmaceuticals (VNDA)
Common SharesNot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Address
2200 Pennsylvania Avenue North West
Suite 300 E
Washington
DC
USA
20037
Telephone
+1 202 7343428
Forecast key dates
| Name | Key Date |
|---|---|
| Vanda Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2026 | 2026-07-31T08:00:00 |
| Vanda Pharmaceuticals Inc Second Quarter Earnings Results for 2026 | 2026-07-31T00:00:00 |
| Vanda Pharmaceuticals Inc Annual General Meeting for 2026 | 2026-06-05T09:00:00 |
| Vanda Pharmaceuticals Inc First Quarter Earnings Conference Call for 2026 | 2026-05-08T16:30:00 |
| Vanda Pharmaceuticals Inc First Quarter Earnings Results for 2026 | 2026-05-08T00:00:00 |
| Vanda Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-02-13T16:30:00 |
| Vanda Pharmaceuticals Inc Fourth Quarter Earnings Results for 2025 | 2026-02-13T00:00:00 |
| Vanda Pharmaceuticals Inc Annual Report for 2025 | 2026-02-13T00:00:00 |
| Vanda Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-06T16:30:00 |
| Vanda Pharmaceuticals Inc Third Quarter Earnings Results for 2025 | 2025-11-06T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.